The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
However, it is important to note that BPC-157 is not approved by the FDA for human use and is not available as an approved treatment at reputable medical practices, including ours
An example of a peptide complementary to BPC-157 is thymosin beta-4 (TB4)
The Role of Cancer Pre-Screening Scientific Rationale for Oncological Screening The proangiogenic properties of BPC-157 and TB-500 raise notable concerns regarding their use in individuals who may harbor subclinical or undiagnosed malignancies
